Cargando…

The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection

BACKGROUND: Faster fibrosis progression and hepatic steatosis are hallmarks of HIV/HCV coinfection. A single nucleotide polymorphism (SNP) of the PNPLA3-gene is associated with development of non-alcoholic steatohepatitis and a worse outcome in alcoholic liver disease. However, the role of PNPLA3 rs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scheiner, Bernhard, Mandorfer, Mattias, Schwabl, Philipp, Payer, Berit Anna, Bucsics, Theresa, Bota, Simona, Aichelburg, Maximilian C., Grabmeier-Pfistershammer, Katharina, Stättermayer, Albert, Ferenci, Peter, Trauner, Michael, Peck-Radosavljevic, Markus, Reiberger, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4658167/ https://www.ncbi.nlm.nih.gov/pubmed/26599080 http://dx.doi.org/10.1371/journal.pone.0143429

Ejemplares similares

Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease: A retrospective study
por: Scheiner, Bernhard, et al.
Publicado: (2016)

Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna
por: Steiner, Sebastian, et al.
Publicado: (2017)

Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients
por: Chromy, David, et al.
Publicado: (2017)

Impact of patatin‐like phospholipase domain containing 3 rs738409 G/G genotype on hepatic decompensation and mortality in patients with portal hypertension
por: Mandorfer, M., et al.
Publicado: (2018)

The impact of hepatic steatosis on portal hypertension
por: Semmler, Georg, et al.
Publicado: (2019)

Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension
por: Scheiner, Bernhard, et al.
Publicado: (2019)

Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension
por: Semmler, Georg, et al.
Publicado: (2019)

Influence of Genetic Variants on Disease Regression and Outcomes in HCV-Related Advanced Chronic Liver Disease after SVR
por: Semmler, Georg, et al.
Publicado: (2021)

The ‘Viennese epidemic’ of acute HCV in the era of direct‐acting antivirals
por: Chromy, David, et al.
Publicado: (2022)

Proton Pump Inhibitor Intake neither Predisposes to Spontaneous Bacterial Peritonitis or Other Infections nor Increases Mortality in Patients with Cirrhosis and Ascites
por: Mandorfer, Mattias, et al.
Publicado: (2014)

Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension
por: Semmler, Georg, et al.
Publicado: (2019)

Impact of Early Initiation of Antiretroviral Therapy in Patients with Acute HIV Infection in Vienna, Austria
por: Herout, Sandra, et al.
Publicado: (2016)

PNPLA3 rs738409 Polymorphism Predicts Development and Severity of Hepatic Steatosis but Not Metabolic Syndrome in Celiac Disease
por: Tortora, Raffaella, et al.
Publicado: (2018)

The PNPLA3 Genetic Variant rs738409 Influences the Progression to Cirrhosis in HIV/Hepatitis C Virus Coinfected Patients
por: Núñez-Torres, Rocío, et al.
Publicado: (2016)

The rs738409 polymorphism of the PNPLA3 gene is associated with hepatic steatosis and fibrosis in Brazilian patients with chronic hepatitis C
por: Manchiero, Caroline, et al.
Publicado: (2017)

Non‐invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease
por: Simbrunner, Benedikt, et al.
Publicado: (2020)

Association of CMV-Specific T Cell-Mediated Immunity with CMV DNAemia and Development of CMV Disease in HIV-1–Infected Individuals
por: Aichelburg, Maximilian C., et al.
Publicado: (2015)

Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon‐Free Therapy
por: Mandorfer, Mattias, et al.
Publicado: (2019)

Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis
por: Simbrunner, Benedikt, et al.
Publicado: (2020)

Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease
por: Scheiner, Bernhard, et al.
Publicado: (2018)

Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease
por: Scheiner, Bernhard, et al.
Publicado: (2019)

Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease
por: Semmler, Georg, et al.
Publicado: (2021)

Circulating MiRNA-122 Levels Are Associated with Hepatic Necroinflammation and Portal Hypertension in HIV/HCV Coinfection
por: Jansen, Christian, et al.
Publicado: (2015)

PNPLA3 rs738409 Polymorphism Associated with Hepatic Steatosis and Advanced Fibrosis in Patients with Chronic Hepatitis C Virus: A Meta-Analysis
por: Fan, Jia-Hao, et al.
Publicado: (2016)

PNPLA3 rs738409 underlies treatment response in nonalcoholic fatty liver disease
por: Wang, Jin-Zhi, et al.
Publicado: (2018)

No Correlation between PNPLA3 rs738409 Genotype and Fatty Liver and Hepatic Cirrhosis in Japanese Patients with HCV
por: Nakamura, Masato, et al.
Publicado: (2013)

Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites
por: Thaler, Johannes, et al.
Publicado: (2021)

Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis
por: Burghart, Lukas, et al.
Publicado: (2021)

The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomes
por: Hartl, Lukas, et al.
Publicado: (2021)

Hepatic Steatosis in Lean Patients: Risk Factors and Impact on Mortality
por: Unger, Lukas W., et al.
Publicado: (2019)

The Risk of Cirrhosis and Its Complications Based on PNPLA3 rs738409 G Allele Frequency
por: Shao, Xue, et al.
Publicado: (2022)

Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension
por: Paternostro, Rafael, et al.
Publicado: (2018)

Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease
por: Hotta, Kikuko, et al.
Publicado: (2010)

Transjugular intrahepatic portosystemic shunts (TIPS) for the prevention of variceal re-bleeding – A two decades experience
por: Bucsics, Theresa, et al.
Publicado: (2018)

Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function
por: Scheiner, Bernhard, et al.
Publicado: (2018)

Impact of ammonia levels on outcome in clinically stable outpatients with advanced chronic liver disease
por: Balcar, Lorenz, et al.
Publicado: (2023)

Perceptions on the management of varices and on the use of albumin in patients with cirrhosis among GI specialists in Austria
por: Pfisterer, Nikolaus, et al.
Publicado: (2020)

Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma
por: Scheiner, Bernhard, et al.
Publicado: (2019)

The rs738409 G Allele in PNPLA3 Is Associated With a Reduced Risk of COVID-19 Mortality and Hospitalization
por: Innes, Hamish, et al.
Publicado: (2021)

Type 2 Diabetes, PNPLA3 rs738409 Polymorphism, and the Risk of Liver Cirrhosis: Analysis of Taiwan Biobank
por: Hsueh, Kuan-Chun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rs4idpnbhmntoojspvqi4938li